rosiglitazone has been researched along with Infarction, Middle Cerebral Artery in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (60.00) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, ZA; Huang, TT; Li, PY; Li, Y; Lu, BW; Wen, DX; Xuan, W; Yu, WF; Zhang, YM; Zhou, NY; Zhu, ZY | 1 |
| Huang, HG; Lin, YH; Lou, M; Sun, JZ; Wen, SQ; Zhang, FH | 1 |
| Ballesteros, I; Corbí, ÁL; Cuartero, MI; Hamilton, JA; Lizasoain, I; Moraga, A; Moro, MA; Nombela, F; Vivancos, J | 1 |
| Cai, W; Chen, J; Han, L; Hu, X; Leak, RK; Li, P; Liu, J; Mao, L; Xu, Y | 1 |
| Chen, HH; Duquette, PM; Harper, ME; Lewandowski, AJ; Qin, Z; Rai, PS; Schock, SC; Seifert, EL; Thompson, CS; Xu, J | 1 |
| Ballesteros, I; Caso, JR; Fernández-López, D; Hurtado, O; Lizasoain, I; Moro, MA; Nombela, F; Pereira, MP; Pradillo, JM; Serena, J; Sobrado, M; Vivancos, J | 1 |
| Allahtavakoli, M; Arababadi, MK; Javanmardi, K; Moloudi, R; Shamsizadeh, A | 1 |
| Aronowski, J; Cui, Z; Grotta, JC; Strong, R; Sun, G; Tsien, JZ; Zhang, J; Zhao, X | 1 |
| Cheng, Y; Liang, H; Sun, GM; Sun, L; Xu, YW | 1 |
| Blankenship, DA; Gamboa, J; Hilow, E; Karl, M; Landreth, GE; Niemi, JP; Sundararajan, S | 1 |
| Boscá, L; Cárdenas, A; Castillo, J; Dávalos, A; Hurtado, O; Lizasoain, I; Lorenzo, P; Moro, MA; Pereira, MP; Serena, J; Vivancos, J | 1 |
| Chen, JJ; Cheung, WM; Lin, H; Lin, TN; Liou, JY; Shyue, SK; Wu, JS; Wu, KK | 1 |
| Chen, J; Graham, SH; Hong, Z; Luo, Y; Signore, AP; Wang, S; Yin, W; Zhang, F | 1 |
| Hurtado, O; Lizasoain, I; Lorenzo, P; Mallolas, J; Morales, JR; Moro, MA; Nombela, F; Pereira, MP; Romera, A; Romera, C; Serena, J; Vivancos, J | 1 |
| Sun, F; Xiang, J; Xiong, N; Zhao, H | 1 |
15 other study(ies) available for rosiglitazone and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Rosiglitazone ameliorates tissue plasminogen activator-induced brain hemorrhage after stroke.
Topics: Anilides; Animals; Anti-Inflammatory Agents; Blood-Brain Barrier; Hypoglycemic Agents; Infarction, Middle Cerebral Artery; Injections, Intraperitoneal; Intracranial Hemorrhages; Lectins, C-Type; Male; Mannose Receptor; Mannose-Binding Lectins; Mice; Mice, Inbred C57BL; Nitric Oxide Synthase Type II; Plasminogen Activators; PPAR gamma; Receptors, Cell Surface; Rosiglitazone; Stroke; Tissue Plasminogen Activator | 2019 |
Rosiglitazone attenuates hyperglycemia-enhanced hemorrhagic transformation after transient focal ischemia in rats.
Topics: Animals; Blood Glucose; Collagen Type IV; Glucose Transporter Type 1; Hemoglobins; Hyperglycemia; Hypoglycemic Agents; Immunohistochemistry; Infarction, Middle Cerebral Artery; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Nervous System Diseases; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2013 |
N2 neutrophils, novel players in brain inflammation after stroke: modulation by the PPARγ agonist rosiglitazone.
Topics: Brain; Encephalitis; Infarction, Middle Cerebral Artery; Neuroprotective Agents; Neutrophils; PPAR gamma; Rosiglitazone; Stroke; Thiazolidinediones | 2013 |
Rosiglitazone Promotes White Matter Integrity and Long-Term Functional Recovery After Focal Cerebral Ischemia.
Topics: Animals; Brain Ischemia; Disease Models, Animal; Infarction, Middle Cerebral Artery; Male; Mice; Mice, Inbred C57BL; Microglia; Oligodendroglia; PPAR gamma; Recovery of Function; Reperfusion; Rosiglitazone; Thiazolidinediones; White Matter | 2015 |
Rescue of neurons from ischemic injury by peroxisome proliferator-activated receptor-gamma requires a novel essential cofactor LMO4.
Topics: Adaptor Proteins, Signal Transducing; Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cell Death; Cell Hypoxia; Cells, Cultured; Cerebral Cortex; Disease Models, Animal; Electrophoretic Mobility Shift Assay; Embryo, Mammalian; Gene Expression Regulation; Glucose; Homeodomain Proteins; Hypoglycemic Agents; Immunoprecipitation; Infarction, Middle Cerebral Artery; Kainic Acid; LIM Domain Proteins; Mice; Mice, Knockout; N-Methylaspartate; Neurons; Oxygen; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; PPAR gamma; Rosiglitazone; Signal Transduction; Superoxide Dismutase; Thiazolidinediones; Trans-Activators; Transcription Factors | 2008 |
Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPARgamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke.
Topics: Animals; Arachidonate 5-Lipoxygenase; Brain; Brain Infarction; Infarction, Middle Cerebral Artery; Leukotriene B4; Lipoxins; Mice; Neuroprotective Agents; PPAR gamma; Rats; Rosiglitazone; Stroke; Thiazolidinediones | 2009 |
Delayed post ischemic treatment with Rosiglitazone attenuates infarct volume, neurological deficits and neutrophilia after embolic stroke in rat.
Topics: Animals; Brain Infarction; Brain Ischemia; Cell Death; Disease Models, Animal; DNA Fragmentation; Encephalitis; Hypoglycemic Agents; Infarction, Middle Cerebral Artery; Leukocyte Count; Male; Neuroprotective Agents; Neutrophils; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome | 2009 |
Neuronal PPARgamma deficiency increases susceptibility to brain damage after cerebral ischemia.
Topics: Animals; Astrocytes; Brain; Cells, Cultured; Coculture Techniques; Female; Gene Expression; Infarction, Middle Cerebral Artery; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neuroglia; Neurons; Neuroprotective Agents; Oxidative Stress; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2009 |
12/15-Lipoxygenase inhibitor baicalein suppresses PPAR gamma expression and nuclear translocation induced by cerebral ischemia/reperfusion.
Topics: Anilides; Animals; Antioxidants; Cell Nucleus; Cerebral Cortex; Cytosol; Disease Models, Animal; Flavanones; Hypoglycemic Agents; Infarction, Middle Cerebral Artery; Male; PPAR gamma; Protein Transport; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Rosiglitazone; Thiazolidinediones; Time Factors; Up-Regulation | 2010 |
Extension of the neuroprotective time window for thiazolidinediones in ischemic stroke is dependent on time of reperfusion.
Topics: Animals; Behavior, Animal; Blood Pressure; Brain; Brain Ischemia; Cell Adhesion Molecules; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Infarction, Middle Cerebral Artery; Leukocytes; Male; Neuroprotective Agents; Pioglitazone; Rats; Rats, Wistar; Regional Blood Flow; Reperfusion; Rosiglitazone; Stroke; Thiazolidinediones | 2010 |
Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms.
Topics: Animals; Anti-Inflammatory Agents; Cyclooxygenase 2; Disease Models, Animal; Drug Administration Schedule; Electrophoresis, Gel, Two-Dimensional; Gene Expression Regulation, Enzymologic; I-kappa B Proteins; Infarction, Middle Cerebral Artery; Male; Matrix Metalloproteinase 9; Neuroprotective Agents; NF-kappa B; NF-KappaB Inhibitor alpha; Nitrates; Nitric Oxide Synthase Type II; Nitrites; Oligonucleotide Array Sequence Analysis; PPAR gamma; Prostaglandin D2; Rats; Rats, Inbred F344; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Time Factors | 2006 |
15d-prostaglandin J2 protects brain from ischemia-reperfusion injury.
Topics: Adenoviridae; Animals; Apoptosis; Caspase 3; Caspases; Cells, Cultured; Cyclooxygenase 1; Gene Transfer Techniques; Genetic Therapy; Heme Oxygenase-1; Infarction, Middle Cerebral Artery; Male; Necrosis; Neurons; Neuroprotective Agents; PPAR gamma; Prostaglandin D2; Rats; Rats, Long-Evans; Reperfusion Injury; Rosiglitazone; Thiazolidinediones; Vasodilator Agents | 2006 |
Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
Topics: Anilides; Animals; Animals, Newborn; Behavior, Animal; Blood Pressure; Body Temperature; Brain Ischemia; Cells, Cultured; Cerebral Infarction; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Gene Expression; Gene Expression Regulation; Granulocyte Colony-Stimulating Factor; Immunohistochemistry; Infarction, Middle Cerebral Artery; Intercellular Adhesion Molecule-1; Interleukin-3; Lectins; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Microglia; Neuroprotective Agents; Peroxidase; PPAR gamma; Psychomotor Performance; Recombinant Fusion Proteins; Recombinant Proteins; Reperfusion; Rosiglitazone; Thiazolidinediones | 2006 |
Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARgamma target gene involved in neuroprotection.
Topics: Animals; Astrocytes; Benzamides; Blotting, Western; Brain; Cells, Cultured; Chromatography, High Pressure Liquid; Coculture Techniques; Excitatory Amino Acid Transporter 2; Gene Expression; Glutamic Acid; Hypoglycemic Agents; Infarction, Middle Cerebral Artery; Ischemic Preconditioning; Male; Neurons; PPAR gamma; Promoter Regions, Genetic; Pyridines; Rats; Rats, Inbred F344; Rats, Wistar; Response Elements; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2007 |
Effect of Rosiglitazone Maleate on inflammation following cerebral ischemia/reperfusion in rats.
Topics: Animals; Brain; Dose-Response Relationship, Drug; Infarction, Middle Cerebral Artery; Inflammation; Interleukin-6; Male; Neuroprotective Agents; Rats; Rats, Wistar; Reperfusion Injury; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2007 |